HYTN Innovations Announces Spin-off of Peptide Development Labs
HYTN Innovations (CSE: HYTN) has officially announced the spin-off of its subsidiary, Peptide Development Labs (PDL). The transaction will be executed via a share exchange mechanism, allowing existing HYTN shareholders to receive common shares in PDL. The move is designed to separate the core business operations of HYTN from the specialized peptide development division. This structural change aims to provide both entities with more focused management and distinct strategic directions for future growth.
Tickers: $HYTN